Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 - Business Wire

Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201  Business Wire

Novus Therapeutics announces that it has dosed the first patients in a phase 2a trial of OP0201, the lead product candidate for otitis media.



Comments

Popular posts from this blog

Summary of Society for Maternal-Fetal Medicine (SMFM) Consult Series #52: Diagnosis and management of fetal growth restriction - Contemporary Obgyn

Sarcoidosis: Causes, Symptoms, Diagnosis & Treatment